The « Polyendocrine » Part: Which Glands Are Involved in PMOS

« Polyendocrine » means several hormone-producing glands are involved rather than the ovary alone. The hypothalamus, pituitary gland and ovaries work as a signalling chain, with the adrenal glands contributing androgens alongside. In PMOS the communication within that chain runs differently, and no single gland is failing.

Key takeaways

• « Polyendocrine » means more than one hormone-producing gland is involved, which is why the new name no longer points at the ovary alone.
• Three structures work as a chain: the hypothalamus, the pituitary gland, and the ovaries.
• The adrenal glands contribute androgens as well, which is part of why the picture is not purely ovarian.
• In polyendocrine metabolic ovarian syndrome (PMOS, formerly PCOS), signalling within that chain runs differently rather than one gland failing.
• No single gland is broken. The pattern is in how they communicate.

What does « polyendocrine » mean?

More than one endocrine gland.

Endocrine glands produce hormones and release them into the bloodstream. « Poly » means several. So the term says that this condition involves several of them working together, rather than one organ malfunctioning on its own.

That was part of the reasoning behind the renaming. The old name pointed at the ovary and at an ovarian appearance, which described where something is visible rather than where it comes from.

How is the chain supposed to work?

Three structures, in sequence.

1. The hypothalamus, in the brain, releases gonadotropin-releasing hormone in pulses. The rate of those pulses is itself a signal.¹
2. The pituitary gland, just below it, responds by producing two hormones: luteinizing hormone (LH) and follicle-stimulating hormone (FSH). How much of each depends partly on how fast the pulses arrive.¹
3. The ovaries respond to LH and FSH. FSH drives a group of follicles to grow; LH acts on the cells that produce ovarian androgens and, later, triggers the release of an egg.¹

The ovaries then send hormones back up the chain, adjusting what the hypothalamus and pituitary do next. It is a loop, not a one-way instruction.

What runs differently in PMOS?

The pulse rate, and what follows from it.

In many people with PMOS, altered hypothalamic signalling favors LH production relative to FSH, which can contribute to increased ovarian androgen production and disrupted follicle development.

Two consequences follow:

• Androgen production increases
• Follicle selection stalls (see why follicles start and stop)

Note what is not happening here. No gland has failed. Each is doing what it does in response to the signals it receives. The pattern sits in the signalling itself.

Easy@Home Ovulation Test Strips

$9.99

Shop Now →

Where do the adrenal glands come in?

They produce androgens too.

The adrenal glands, which sit above the kidneys, are a separate source of androgens from the ovaries.¹ In a meaningful proportion of people with this condition, the adrenal contribution is part of the androgen picture rather than the ovary accounting for all of it.

This matters for the name. A condition in which two separate glands contribute androgens, under instruction from a third and a fourth, is not well described as an ovarian disorder. It is reasonably described as polyendocrine.

Where does the pancreas fit?

Through insulin.

Insulin, produced by the pancreas, acts alongside luteinizing hormone on the ovarian cells that make androgens, increasing their output.¹ It also reduces how much sex hormone-binding globulin the liver produces, which raises the proportion of circulating testosterone that is biologically active.¹

So the metabolic side is not a separate track running in parallel. It feeds into the same ovarian step that LH does.

Counting up: hypothalamus, pituitary, ovary, adrenal, pancreas. Five structures, one interacting system.

Hypothalamus · Pituitary · Ovary · Adrenal · Pancreas

Why does this matter for how care works?

Because it explains why assessment covers more than one thing.

If the condition were purely ovarian, a cycle-focused assessment would be sufficient. Because it is not, the guideline recommends that once a diagnosis is made, assessment and management address reproductive, metabolic, cardiovascular, dermatologic, sleep and psychological features (DOI: 10.1210/clinem/dgad463).²

That breadth follows directly from the biology rather than being added on. Our article on what the guideline says about long-term health goes through what the guideline covers.

What this means for tracking with Premom

None of the signalling described here is visible in a tracking app. Pulse rates, gonadotropin levels, adrenal androgens and insulin are all measured clinically, and most are not measured routinely at all.

What a record of cycle dates over months shows is one downstream consequence, the pattern of cycles, which is one output of the system rather than a view into it.

Premom is an ovulation tracking application. It is not intended to diagnose, treat, cure, or prevent any disease, including PMOS. The information provided is for educational purposes and should not replace consultation with a healthcare provider.

When to talk to a clinician

The information here is general and is not a basis for self-diagnosis. Speak with a clinician if:

• You have a diagnosis and want to understand what is being assessed and why
• You have had hormone results you do not understand
• Your cycles are consistently long or vary widely from month to month
• You have symptoms that concern you and have not been assessed

About PMOS

Polycystic ovary syndrome was renamed polyendocrine metabolic ovarian syndrome (PMOS) by international consensus published in The Lancet on 12 May 2026.³ A three-year transition runs to 2028, and both names remain in clinical use. Diagnostic criteria did not change, and an existing PCOS diagnosis remains valid.

In adults, diagnosis requires two of three features: clinical or biochemical hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology on ultrasound or elevated anti-Müllerian hormone, after other causes are excluded.² Reported prevalence varies with the criteria applied; the guideline reports 10–13% (DOI: 10.1210/clinem/dgad463).²

Read nextAMH and PMOS: What the Test Does and Doesn’t Settle→